Prosecution Insights
Last updated: May 29, 2026
Application No. 18/815,499

CORNEAL IMPLANT SYSTEMS AND METHODS

Non-Final OA §103§112§DOUBLEPATENT
Filed
Aug 26, 2024
Priority
Mar 23, 2021 — continuation of 12/070,422
Examiner
VARGOT, MATHIEU D
Art Unit
1742
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Allotex Inc.
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
1y 9m
Est. Remaining
83%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
729 granted / 1179 resolved
-3.2% vs TC avg
Strong +21% interview lift
Without
With
+21.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
18 currently pending
Career history
1217
Total Applications
across all art units

Statute-Specific Performance

§101
0.1%
-39.9% vs TC avg
§103
76.2%
+36.2% vs TC avg
§102
1.1%
-38.9% vs TC avg
§112
4.7%
-35.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1179 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 1.Claims 7 and 8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 7, line 2, it is unclear what “fluid” is being referred to and such should clearly be set forth. As it stands, any fluid that would be within the lenticule will be considered to be encompassed by the claim. Also, in claim 7, line 3, “the controller” lacks antecedent basis. Claim 8, line 3, “the hydrating fluid” also lacks antecedent basis. 2.The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mueller 2014/0264980 (see paragraphs 0046-0053; Figs. 8 and 16C). Mueller discloses the basic claimed system for forming a corneal implant including a receptacle (64 in Fig. 16C) configured to receive a lenticule (52) formed from corneal tissue and a cutting apparatus including a laser to cut the lenticule, the applied reference essentially failing to disclose one or more optical elements to direct the laser. It is nothing but conventional in the art to employ such optics—Official Notice is hereby taken of this—and such would have been an obvious modification to the system of Mueller to facilitate the cutting as desired. Concerning maintaining the state of the lenticule, paragraph 0052, line 3 teaches a “controlled environment” in which all operations are performed and such would have clearly been used in the cutting and for the receptacle of Fig. 16C. Paragraph 0052, line 4 discloses “same state of hydration”, thereby meeting instant claim 2. Employing a temperature element or humidifier is nothing but conventional in the art—Official Notice is hereby taken of this—to maintain a state of a material to be processed and including such as part of the receptacle would have been obvious to ensure that the state of the lenticule is maintained. Given that the state of the lenticule is to be maintained, then a sealed enclosure as recited in instant claims 4 and 5 would obviously have been useful to facilitate the maintenance. Further, it is submitted that sealed enclosures to process biological substrates are well known in the art—Official Notice is also hereby taken of this—and such would have been an obvious modification to the system of Mueller to facilitate the “conduction in a controlled environment” so that the lenticule is “maintained in the same state of hydration” as taught by Mueller. Obviously, if the lenticule is contained within an enclosure, and is to be cut with a laser, there would beneficially be a laser transparent window in or on the enclosure. It is submitted that such windows are conventional in the art—Official Notice is also taken of this—and such would have been an obvious feature in the system of the applied reference to allow the laser beam to pass through and perform the ablation of the lenticule. 3.Claim(s) 7 and 8 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mueller 2014/02649809 in view of Swinger 5,647,865 (see Fig. 3 and col. 5, lines 1-17). Mueller discloses the basic claimed system as set forth in paragraph 2, supra, including a receptacle (64 in Fig. 16C) with one or more evacuation mechanisms (86 in Fig. 16C) that are connected to a vacuum source (paragraph 0066) to hold the lenticule in place and to draw any fluid therefrom (paragraph 0079), the primary reference essentially lacking the aspect of the receptacle including a recess to receive the lenticule and fluid. Swinger shows a similar receptacle that has a recess configured to receive a lenticule and such would have been an obvious modification to the receptacle of Mueller to facilitate the accurate placement and cutting of the lenticule. Mueller (see paragraphs 0073 and 0083) discloses that the steps of the process are automated under the control of a controller, and clearly the laser cutting would have been under such control. 4.The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 5.Claims 1-8 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 10,449,090. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the previously issued patent recite substantially the same or similar system with additional features that are not recited in the instant claims. It is always within the skill level of the art to eliminate features that are not needed. 6.Claims 1-8 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 10,952,900. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the previously issued patent recite substantially the same or similar system with additional features that are not recited in the instant claims. It is always within the skill level of the art to eliminate features that are not needed. 7.Claims 1-8 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 12,070,422. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the previously issued patent recite substantially the same or similar system with additional features that are not recited in the instant claims. It is always within the skill level of the art to eliminate features that are not needed. 8.Any inquiry concerning this communication or earlier communications from the examiner should be directed to MATHIEU D VARGOT whose telephone number is (571)272-1211. The examiner can normally be reached on Mon-Fri from 9 to 6. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christina A Johnson, can be reached at telephone number 571 272-1176. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center to authorized users only. Should you have questions about access to the USPTO patent electronic filing system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via a variety of formats. See MPEP § 713.01. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/InterviewPractice. /MATHIEU D VARGOT/Primary Examiner, Art Unit 1742
Read full office action

Prosecution Timeline

Aug 26, 2024
Application Filed
Apr 10, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12629911
METHOD FOR DRY-FORMING A CELLULOSE BOTTLE, CELLULOSE BOTTLE FORMING UNIT AND CELLULOSE BOTTLE
2y 7m to grant Granted May 19, 2026
Patent 12629906
SYSTEM AND METHOD TO MANUFACTURE A CONTACT LENS WITH AN EMBEDDED ELEMENT
2y 7m to grant Granted May 19, 2026
Patent 12623417
FIXATION FIXTURE, PROCESSING DEVICE AND METHOD FOR MAKING LIQUID CRYSTAL LENS
2y 8m to grant Granted May 12, 2026
Patent 12623418
Functional Layer Application System
2y 5m to grant Granted May 12, 2026
Patent 12605045
AN ENDOSCOPE AND A METHOD FOR MOULDING TRANSPARENT WINDOWS OF AN ENDOSCOPE
2y 12m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
83%
With Interview (+21.2%)
3y 6m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1179 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month